Clarithromycin treatment and QT prolongation in childhood

Acta Paediatrica, International Journal of Paediatrics

Volumn 95, Issue 12, 2006, Pages 1694-1696

  Germanakis, Ioannis ^a,b   Galanakis, Emmanouil ^a   Parthenakis, Fragiskos ^a   Vardas, Panos E ^a   Kalmanti, Maria ^a  

^a UNIVERSITY OF CRETE   (Greece)

^b UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

Author keywords

Arrhythmia; Childhood; Clarithromycin; QT prolongation; Side effects

Indexed keywords

CLARITHROMYCIN;

ADOLESCENT; ARTICLE; CHILD; CLINICAL ARTICLE; DISEASE SEVERITY; FEMALE; HEART ARRHYTHMIA; HIGH RISK PATIENT; HUMAN; INFANT; MALE; PRIORITY JOURNAL; QRS COMPLEX; QT INTERVAL; QT PROLONGATION; RESPIRATORY TRACT INFECTION; RR INTERVAL;

ADOLESCENT; ANTI-BACTERIAL AGENTS; CHILD; CHILD, PRESCHOOL; CLARITHROMYCIN; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; INFANT; LONG QT SYNDROME; MALE; RESPIRATORY TRACT INFECTIONS;

EID: 33845269339     PISSN: 08035253     EISSN: 16512227     Source Type: Journal    
DOI: 10.1080/08035250600764800     Document Type: Article

References (15)

1. Yap YG, Camm AJ. Drug induced QT prolongation and torsades de pointes. Heart 2003;89:1363-72.
2. Vallejo Camazon N, Rodriguez Pardo D, Sanchez Hidalgo A, Tornos Mas MP, Ribera E, Soler Soler J. Ventricular tachycardia and long QT associated with clarithromycin administration in a patient with HIV infection. Rev Esp Cardiol 2002;55:878-81.
3. Kamochi H, Nii T, Eguchi K, Mori T, Yamamoto A, Shimoda K, et al. Clarithromycin associated with torsades de pointes. Jpn Circ J 1999;63:421-2.
4. Lee KL, Jim MH, Tang SC, Tai YT. QT prolongation and torsades de pointes associated with clarithromycin. Am J Med 1998;104:395-6.
5. Choudhury L, Grais IM, Passman RS. Torsades de pointes due to drug interaction between disopyramide and clarithromycin. Heart Dis 1999;1:206-7.
6. Hayashi Y, Ikeda U, Hashimoto T, Watanabe T, Mitsuhashi T, Shimada K. Torsades de pointes ventricular tachycardia induced by clarithromycin and disopyramide in the presence of hypokalemia. Pacing Clin Electrophysiol 1999;22:672-4.
7. Piquette RK. Torsade de pointes induced by cisapride/clarithromycin interaction. Ann Pharmacother 1999;33:22-6.
8. van Haarst AD, van't Klooster GA, van Gerven JM, Schoemaker RC, van Oene JC, Burggraaf J, et al. The influence of cisapride and clarithromycin on QT intervals in healthy volunteers. Pharmacol Ther 1998;64:542-6.
9. Sekkarie MA. Torsades de pointes in two chronic renal failure patients treated with cisapride and clarithromycin. Am J Kidney Dis 1997;30:437-9.
10. Abbott GW, Sesti F, Splawski I, Buck ME, Lehmann MH, Timothy KW, et al. MiRP1 forms IKr potassium channels with HERG and is associated with cardiac arrhythmia. Cell 1999;97:175-87.
11. Dilaveris PE. Molecular predictors of drug-induced prolongation of the QT interval. Curr Med Chem Cardiovasc Hematol Agents 2005;3:105-18.
12. Moss AJ. Measurement of the QT interval and the risk associated with QTc interval prolongation: a review. Am J Cardiol 1993;72:23B-5B.
13. Dapro B. Spectrum of drugs prolonging QT interval and the incidence of torsades de pointes. Eur Heart J 2001;3 Suppl K:70-80.
14. Rubart M, Pressler ML, Pride HP, Zipes DP. Electrophysiological mechanisms in a canine model of erythromycin-associated long QT syndrome. Circulation 1993;88:1832-44.
15. Chu S, Wilson DS, Deaton RL, Mackenthun AV, Eason CN, Cavanaugh JH. Single and multiple dose pharmacokinetics of clarithromycin, a new macrolide antimicrobial. J Clin Pharmacol 1993;33:719-26.